Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study (vol 56, pg 770, 2020)

被引：0
作者：
Zamarin, Dmitriy
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2702 / 2702
页数：1
相关论文
共 50 条
  • [41] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
    Tong, T. M. L.
    van der Kooij, M. K.
    Speetjens, F. M.
    van Erkel, A. R.
    van der Meer, R. W.
    Lutjeboer, J.
    van Meerten, E. L. van Persijn
    Martini, C. H.
    Zoethout, R. W. M.
    Tijl, F. G. J.
    Blank, C. U.
    Burgmans, M. C.
    Kapiteijn, E.
    TRIALS, 2022, 23 (01)
  • [42] Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (vol 37, pg 1380, 2019)
    Walker
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2299 - 2299
  • [43] Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
    Landen, Charles N.
    Buckanovich, Ronald J.
    Sill, Michael W.
    Mannel, Robert S.
    Walker, Joan L.
    Disilvestro, Paul A.
    Mathews, Cara A.
    Mutch, David G.
    Hernandez, Marcia L.
    Martin, Lainie P.
    Bishop, Erin
    Gill, Sarah E.
    Gordinier, Mary E.
    Burger, Robert A.
    Aghajanian, Carol
    Liu, Joyce F.
    Moore, Kathleen N.
    Bookman, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (21) : 2537 - 2545
  • [44] Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
    Brown, Jubilee
    Miller, Austin
    Holman, Laura L.
    Backes, Floor
    Nagel, Christa
    Bender, David
    Miller, David S.
    Powell, Matthew A.
    Westin, Shannon N.
    Bonebrake, Albert
    Muller, Carolyn Y.
    Secord, Angeles Alvarez
    Crane, Erin
    Schorge, John
    Tew, William P.
    Sood, Anil K.
    Bookman, Michael A.
    Aghajanian, Carol
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2024, 190 : 283 - 290
  • [45] Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN)
    Robert, Caroline
    Dutriaux, Caroline
    Oppong, Felix Boakye
    Kicinski, Michal
    Routier, Emilie
    Neidhardt, Eve-Marie
    Durando, Xavier
    Baroudjian, Barouyr
    Saiag, Philippe
    Gaudy-Marqueste, Caroline
    Ascierto, Paolo Antonio
    Arance, Ana Maria
    Russillo, Michelangelo
    Perrot, Jean-Luc
    Govaerts, Anne-sophie
    Buhrer, Emanuel
    Schilling, Bastian
    Mandala, Mario
    Lorigan, Paul
    van Akkooi, Alexander Christopher Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9503 - LBA9503
  • [46] A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Dizon, Don S.
    Sill, Michael W.
    Schilder, Jeanne M.
    McGonigle, Kathryn F.
    Rahman, Zia
    Miller, David S.
    Mutch, David G.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (03) : 441 - 445
  • [47] Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
    Copeland, Larry J.
    Brady, Mark F.
    Burger, Robert A.
    Rodgers, William H.
    Huang, Helen Q.
    Cella, David
    O'Malley, David M.
    Street, Daron G.
    Tewari, Krishnansu S.
    Bender, David P.
    Morris, Robert T.
    Lowery, William J.
    Miller, David S.
    Dewdney, Summer B.
    Spirtos, Nick M.
    Lele, Shashikant B.
    Guntupalli, Saketh
    Ueland, Frederick R.
    Glaser, Gretchen E.
    Mannel, Robert S.
    DiSaia, Philip J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4119 - +
  • [48] CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in hemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC)
    Paz-Ares, L.
    Brahmer, J.
    Hellmann, M. D.
    Reck, M.
    O'Byrne, K.
    Borghaei, H.
    Geese, W. J.
    Lu, H.
    Nathan, F. E.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.(vol 405, pg 383, 2025)
    Andre, T.
    Elez, E.
    Lenz, H-J
    LANCET, 2025, 405 (10480) : 700 - 700
  • [50] Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.
    Antonia, Scott Joseph
    Bendell, Johanna C.
    Taylor, Matthew Hiram
    Calvo, Emiliano
    Jaeger, Dirk
    De Braud, Filippo G.
    Ott, Patrick Alexander
    Pietanza, M. Catherine
    Horn, Leora
    Le, Dung T.
    Morse, Michael
    Lopez-Martin, Jose A.
    Ascierto, Paolo Antonio
    Christensen, Olaf
    Grosso, Joseph
    Simon, Jason S.
    Lin, Chen-Sheng
    Eder, Joseph Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345